Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum.
Crinetics Pharmaceuticals is a pharmaceutical company focused on endocrine diseases, with its first FDA-approved product PALSONIFY (paltusotine) launched in October 2025 for acromegaly treatment. The pipeline includes atumelnant in Phase 3 for congenital adrenal hyperplasia... Read more
Sell if holding. Engine safety override at $35.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Crinetics Pharmaceuticals, Inc.
Latest news
- Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $88 — benzinga May 15, 2026 positive
- Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday — benzinga May 11, 2026 neutral
- Oppenheimer Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $84 — benzinga May 11, 2026 positive
- Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $95 — benzinga May 8, 2026 positive
- Crinetics Pharmaceuticals Q1 EPS $(1.23) Beats $(1.25) Estimate, Sales $10.306M Beat $8.512M Estimate — benzinga May 7, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.30: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 7.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $32.95. Score 4.9/10, moderate confidence.
Take-profit target: $72.33 (+104.2% upside). Prior stop was $32.95. Stop-loss: $32.95.
Quality below floor (1.6 < 4.0).
Crinetics Pharmaceuticals, Inc. trades at a P/E of N/A (forward -8.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover CRNX with a consensus score of 4.2/5. Average price target: $83.
What does Crinetics Pharmaceuticals, Inc. do?Crinetics Pharmaceuticals is a pharmaceutical company focused on endocrine diseases, with its first FDA-approved...
Crinetics Pharmaceuticals is a pharmaceutical company focused on endocrine diseases, with its first FDA-approved product PALSONIFY (paltusotine) launched in October 2025 for acromegaly treatment. The pipeline includes atumelnant in Phase 3 for congenital adrenal hyperplasia (CAH) and CRN09682 in Phase 1/2 for SST2-expressing tumors.